Title : Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.

Pub. Date : 2014 Jul

PMID : 24924416






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We assessed whether vandetanib, an inhibitor of VEGF, epidermal growth factor receptor and RET signalling, improved uNTx response when added to fulvestrant (F) in breast cancer patients with bone metastases. vandetanib vascular endothelial growth factor A Homo sapiens